NCT07133425

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.

Detailed description

Primary Objectives * To identify early efficacy signals for SAR445877 in ICI-exposed NSCLC participants * Identify biomarkers related to the mechanism of action in SAR445877 and predictive of response/resistance in ICI-exposed NSCLC participants

Conditions

• Non-Small Cell Lung Cancer
• ICI-refractory

Interventions

Type	Name	Description
DRUG	SAR445877	Given by IV

Timeline

• Start date: 2025-11-06
• Primary completion: 2028-02-01
• Completion: 2030-02-01
• First posted: 2025-08-21
• Last updated: 2026-04-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study